These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9489823)

  • 41. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
    Kumar VA; Wilson SS; Ayaz SI; Levy PD
    Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The pharmacokinetics and absorption of recombinant human relaxin in nonpregnant rabbits and rhesus monkeys after intravenous and intravaginal administration.
    Chen SA; Reed B; Nguyen T; Gaylord N; Fuller GB; Mordenti J
    Pharm Res; 1993 Feb; 10(2):223-7. PubMed ID: 8456068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stability and characterization of recombinant human relaxin.
    Nguyen TH; Shire SJ
    Pharm Biotechnol; 1996; 9():247-74. PubMed ID: 8914194
    [No Abstract]   [Full Text] [Related]  

  • 44. RELAXIN IN THE TREATMENT OF LOCALISED SCLERODERMA.
    WELLS RS
    Trans St Johns Hosp Dermatol Soc; 1963; 49():149-51. PubMed ID: 14116132
    [No Abstract]   [Full Text] [Related]  

  • 45. Relaxins: lessons and limitations.
    Seibold JR
    Curr Rheumatol Rep; 2002 Aug; 4(4):275-6. PubMed ID: 12126574
    [No Abstract]   [Full Text] [Related]  

  • 46. Failure of relaxin inthe treatment of scleroderma.
    JEFFERIS JE; DIXON AS
    Ann Rheum Dis; 1962 Sep; 21(3):295-7. PubMed ID: 14028943
    [No Abstract]   [Full Text] [Related]  

  • 47. [Study on the treatment of diffuse scleroderma using Edtacal].
    Fedorová O
    Vnitr Lek; 1966 Jul; 12(7):682-4. PubMed ID: 4961194
    [No Abstract]   [Full Text] [Related]  

  • 48. Top heart-failure contender serelaxin flops.
    Nat Biotechnol; 2017 Apr; 35(4):297. PubMed ID: 28398333
    [No Abstract]   [Full Text] [Related]  

  • 49. [Observations on the effect of anticoagulants in diffuse scleroderma. Preliminary report].
    Michalowski R; Kudejko T
    Pol Tyg Lek; 1965 Dec; 20(49):1865-6. PubMed ID: 5862129
    [No Abstract]   [Full Text] [Related]  

  • 50. Serum relaxin levels in subjects with multiple sclerosis.
    Garvin R; Burns A
    Ital J Anat Embryol; 2016; 121(1):51-59. PubMed ID: 28872797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic administration of recombinant human relaxin (RHRLX) ameliorates the acute cyclosporine nephrotoxicity in rats.
    Huang X; Cheng Z; Sunga J; Unemori E; Zsebo K
    J Heart Lung Transplant; 2001 Feb; 20(2):253. PubMed ID: 11250506
    [No Abstract]   [Full Text] [Related]  

  • 52. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.
    Aragón-Herrera A; Feijóo-Bandín S; Anido-Varela L; Moraña-Fernández S; Roselló-Lletí E; Portolés M; Tarazón E; Gualillo O; González-Juanatey JR; Lago F
    J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887517
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serelaxin in clinical development: past, present and future.
    Unemori E
    Br J Pharmacol; 2017 May; 174(10):921-932. PubMed ID: 28009437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.
    Weiss G; Teichman S; Stewart D; Nader D; Wood S; Breining P; Unemori E
    BMC Pregnancy Childbirth; 2016 Sep; 16(1):260. PubMed ID: 27596360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New Drugs You Are Going to Read About: Serelaxin, Ularitide, TRV027.
    Kumar VA; Viau D; Levy P
    Curr Emerg Hosp Med Rep; 2015 May; 3(2):66-73. PubMed ID: 26236569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.
    Vitiello M; Abuchar A; Santana N; Dehesa L; Kerdel FA
    J Clin Aesthet Dermatol; 2012 Jul; 5(7):33-43. PubMed ID: 22798974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
    Khanna D; Clements PJ; Furst DE; Korn JH; Ellman M; Rothfield N; Wigley FM; Moreland LW; Silver R; Kim YH; Steen VD; Firestein GS; Kavanaugh AF; Weisman M; Mayes MD; Collier D; Csuka ME; Simms R; Merkel PA; Medsger TA; Sanders ME; Maranian P; Seibold JR;
    Arthritis Rheum; 2009 Apr; 60(4):1102-11. PubMed ID: 19333948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biology of primate relaxin: a paracrine signal in early pregnancy?
    Hayes ES
    Reprod Biol Endocrinol; 2004 Jun; 2():36. PubMed ID: 15200675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination therapies for systemic sclerosis.
    Denton CP; Black CM
    Springer Semin Immunopathol; 2001; 23(1-2):109-29. PubMed ID: 11455851
    [No Abstract]   [Full Text] [Related]  

  • 60. Novel therapeutic strategies in scleroderma.
    Denton CP; Black CM
    Curr Rheumatol Rep; 1999 Oct; 1(1):22-7. PubMed ID: 11123010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.